Sugi Predict

Sugi Predict / Compounds / SCHEMBL15980708

SCHEMBL15980708

SCHEMBL15980708

Cc1cc2c(cc1-c1c(C)noc1C)ncc1c2n([C@H](C)c2ccccn2)c(=O)n1C(C)C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 20/20 0.69
▸ BRD2 P25440 2/20 0.59
▸ BRD3 Q15059 2/20 0.59
▸ CYP3A4 P08684 2/20 0.59
▸ CYP2C9 P11712 2/20 0.59
▸ CACNA1A O00555 1/20 0.59
▸ CHRNA1 P02708 1/20 0.59
▸ CYP2D6 P10635 1/20 0.59
▸ CCL2 P13500 1/20 0.59
▸ KCNA5 P22460 1/20 0.59
▸ TACR1 P25103 1/20 0.59
▸ MAOB P27338 1/20 0.59
▸ CYP2C19 P33261 1/20 0.59
▸ AVPR1A P37288 1/20 0.59
▸ PDE4B Q07343 1/20 0.59
▸ KCNH2 Q12809 1/20 0.59
▸ SCN5A Q14524 1/20 0.59
▸ BRDT Q58F21 1/20 0.59
▸ CREBBP Q92793 1/20 0.59
▸ KCNH3 Q9ULD8 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19730379 0.83 BRD4 (0.81) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL15985143 0.82 BRD4 (1.00) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL20942201 0.81 BRD4 (0.84) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL14756742 0.81 BRD4 (0.84) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL22053929 0.80 BRD4 (0.83) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL22053933 0.80 BRD4 (0.83) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL15980705 0.80 BRD4 (0.49) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL17854807 0.78 BRD4 (0.72) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL1906250 0.78 BRD4 (0.81) BRD4BRD2BRD3CYP3A4CYP2C9
SCHEMBL29516894 0.77 BRD4 (0.71) BRD4BRD2BRD3CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243286-A1 BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME COFERON, INC. (US) 2014-08-28 — — US disclosed
US-20140243322-A1 BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME COFERON, INC. (US) 2014-08-28 — — US disclosed
US-20140243321-A1 BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME COFERON, INC. (US) 2014-08-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243322-A1 BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME BRDT, BRD2, BRD4 BRD4 3/4885BRD2 2/4885BRD3 4/4885
US-20140243286-A1 BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME BRDT, BRD4, BRD1 BRD4 2/4885BRD2 5/4885BRD3 6/4885
US-20140243321-A1 BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME BRDT, BRD4, BRD1 BRD4 2/4885BRD2 5/4885BRD3 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.